FAQs
1. What are prodrugs, and how do they relate to drug delivery?
A prodrug is an inactive compound that becomes an active drug only after it is metabolized or chemically transformed inside the body. This is a chemical delivery strategy used to improve the drug’s solubility, targeting, or absorption, or to reduce its side effects during delivery.
2. How do drug delivery systems address drug bioavailability?
Bioavailability is the fraction of an administered drug that reaches the systemic circulation unchanged. Delivery systems like liposomes, micelles, or specific oral formulations protect the drug from degradation (e.g., in the stomach) and increase its absorption, thereby significantly boosting the amount of active drug available to the body.
3. What is the role of pharmacogenomics in the future of drug delivery?
Pharmacogenomics studies how an individual’s genes affect their response to drugs. In the future, this data will allow for truly personalized medicine. This will guide the design of unique delivery systems that are tailored precisely to a patient’s genetic profile to maximize efficacy and minimize toxicity.
4. What are stimuli-responsive systems?
These delivery systems are designed to release their drug payload only when triggered by specific cues, such as changes in pH (common in tumors or inflamed areas), temperature, light, or ultrasound. This ensures the drug is released exactly at the diseased site, enhancing targeting and reducing side effects.
Reference
1. Vargason, A. M., Anselmo, A. C., & Mitragotri, S. (2021). The evolution of commercial drug delivery technologies. Nature biomedical engineering, 5(9), 951-967.
2. Kim, M. S., Yeom, D. W., Kim, S. R., et al. (2016). Development of a chitosan based double layer-coated tablet as a platform for colon-specific drug delivery. Drug design, development and therapy, 11, 45-57.
3. Sassalos, T. M., & Paulus, Y. M. (2019). Prefilled syringes for intravitreal drug delivery. Clinical Ophthalmology (Auckland, NZ), 13, 701.
4. Rogliani, P., Calzetta, L., Coppola, A., et al. (2017). Optimizing drug delivery in COPD: the role of inhaler devices. Respiratory medicine, 124, 6-14.
5. Bird, D., & Ravindra, N. M. (2020). Transdermal drug delivery and patches—An overview. Medical Devices & Sensors, 3(6), e10069.
6. Vargason, A. M., Anselmo, A. C., & Mitragotri, S. The evolution of commercial drug delivery technologies. Nature biomedical engineering, 5(9), 951-967.
7. Alavi, M., Karimi, N., & Safaei, M. (2017). Application of various types of liposomes in drug delivery systems. Advanced pharmaceutical bulletin, 7(1), 3.
8. El-Sherbiny, I. M., El-Baz, N. M., & Yacoub, M. H. (2015). Inhaled nano-and microparticles for drug delivery. Global Cardiology Science & Practice, 2015(2).
9. Shi, Y., Lammers, T., Storm, G., et al. (2016). Physico-chemical strategies to enhance stability and drug retention of polymeric micelles for tumor-targeted drug delivery. Macromolecular bioscience, 17(1), 10-1002.
10. Tewabe, A., Abate, A., Tamrie, M., et al. (2021). Targeted drug delivery—from magic bullet to nanomedicine: principles, challenges, and future perspectives. Journal of Multidisciplinary Healthcare, 14, 1711-1724.
11. Urquhart, J. (2001). Controlled drug delivery: therapeutic and pharmacological aspects. Journal of internal medicine, 249(S741), 75-94.
12. Senapati, S., Mahanta, A. K., Kumar, S., et al. (2018). Controlled drug delivery vehicles for cancer treatment and their performance. Signal transduction and targeted therapy, 3(1), 7.
13. Glassman, P. M., & Muzykantov, V. R. (2019). Pharmacokinetic and pharmacodynamic properties of drug delivery systems. The Journal of pharmacology and experimental therapeutics, 370(3), 570-580.
14. Zhao, Z., Ukidve, A., Kim, J., et al. (2020). Targeting strategies for tissue-specific drug delivery. Cell, 181(1), 151-167.
15. Kamaly, N., Yameen, B., Wu, J., et al. (2016). Degradable controlled-release polymers and polymeric nanoparticles: mechanisms of controlling drug release. Chemical reviews, 116(4), 2602-2663.
16. Tiwari, G., Tiwari, R., Sriwastawa, B., et al. (2012). Drug delivery systems: An updated review. International journal of pharmaceutical investigation, 2(1), 2.
17. Hakim, L. K., Yazdanian, M., Alam, M., et al. (2021). Biocompatible and biomaterials application in drug delivery system in oral cavity. Evidence‐Based Complementary and Alternative Medicine, 2021(1), 9011226.
18. Alqahtani, M. S., Kazi, M., Alsenaidy, M. A., et al. (2021). Advances in oral drug delivery. Frontiers in pharmacology, 12, 618411.
19. Jin, J. F., Zhu, L. L., Chen, M., et al. (2015). The optimal choice of medication administration route regarding intravenous, intramuscular, and subcutaneous injection. Patient preference and adherence, 9, 923-942.
20. Kang, J. H., & Ko, Y. T. (2023). Intraosseous administration into the skull: potential blood–brain barrier bypassing route for brain drug delivery. Bioengineering & Translational Medicine, 8(2), e10424.
21. Ibrahim, M., Verma, R., & Garcia-Contreras, L. (2015). Inhalation drug delivery devices: technology update. Medical Devices: Evidence and Research, 8, 131-139.
22. Dudhat, K. R., & Patel, H. V. (2022). Influence of particle size and particle deposition of inhaled medication in lung disease: a comrehensive review. International Journal of Pharmaceutical Sciences and Drug Research, 14(1), 141-157.
23. Chrystyn, H., & Lavorini, F. (2020). The dry powder inhaler features of the Easyhaler that benefit the management of patients. Expert Review of Respiratory Medicine, 14(4), 345-351.
24. Anderson, P. (2006). Use of Respimat® soft Mist™ inhaler in COPD patients. International journal of chronic obstructive pulmonary disease, 1(3), 251-259.
25. Alany, R. (2017). Topical and transdermal formulation and drug delivery. Pharmaceutical development and technology, 22(4), 457-457.
26. Boden, W. E., Padala, S. K., Cabral, K. P., et al. (2015). Role of short-acting nitroglycerin in the management of ischemic heart disease. Drug Design, Development and Therapy, 9, 4793-4805.
27. Cooper, W., Ray, S., Aurora, S. K., et al. (2022). Delivery of Dihydroergotamine Mesylate to the Upper Nasal Space for the Acute Treatment of Migraine: Technology in Action. Journal of Aerosol Medicine and Pulmonary Drug Delivery, 35(6), 321.
28. Shen, J., Gao, H., Chen, L., et al. (2023). Eyedrop-based macromolecular ophthalmic drug delivery for ocular fundus disease treatment. Science Advances, 9(4), eabq3104.
29. Zhang, Z., Li, X., Zhang, W., et al. (2021). Drug delivery across barriers to the middle and inner ear. Advanced functional materials, 31(44), 2008701.
30. Awad, A., Hollis, E., Goyanes, A., et al. (2023). 3D printed multi-drug-loaded suppositories for acute severe ulcerative colitis. International Journal of Pharmaceutics: X, 5, 100165.
31. Hoc, D., & Haznar-Garbacz, D. (2021). Foams as unique drug delivery systems. European Journal of Pharmaceutics and Biopharmaceutics, 167, 73-82.
32. Gao, Y., Yuan, A., Chuchuen, O., et al. (2015). Vaginal deployment and tenofovir delivery by microbicide gels. Drug delivery and translational research, 5(3), 279-294.
33. Parkash, V., Maan, S., Yadav, S. K., et al. (2011). Fast disintegrating tablets: Opportunity in drug delivery system. Journal of Advanced Pharmaceutical Technology & Research, 2(4), 223.
34. Jacob, S., Nair, A. B., & Shah, J. (2020). Emerging role of nanosuspensions in drug delivery systems. Biomaterials research, 24(1), 3.
35. Garg, T., Rath, G., & Goyal, A. K. (2015). Comprehensive review on additives of topical dosage forms for drug delivery. Drug delivery, 22(8), 969-987.
36. Wojtyłko, M., Lamprou, D. A., Froelich, A., et al. (2024). 3D-printed solid oral dosage forms for mental and neurological disorders: Recent advances and future perspectives. Expert Opinion on Drug Delivery, 21(11), 1523-1541.
37. Brissos, S., & Balanzá-Martínez, V. (2024). Long-acting antipsychotic treatments: focus on women with schizophrenia. Therapeutic Advances in Psychopharmacology, 14, 20451253241263715.
38. Itzoe, M., & Guarnieri, M. (2017). New developments in managing opioid addiction: impact of a subdermal buprenorphine implant. Drug design, development and therapy, 11, 1429-1437.
39. Manzari, M. T., Shamay, Y., Kiguchi, H., et al. (2021). Targeted drug delivery strategies for precision medicines. Nature Reviews Materials, 6(4), 351-370.
40. Daraee, H., Etemadi, A., Kouhi, M., et al. (2016). Application of liposomes in medicine and drug delivery. Artificial cells, nanomedicine, and biotechnology, 44(1), 381-391.
41. Ramaswami, R., Uldrick, T. S., Polizzotto, M. N., et al. (2019). A pilot study of liposomal doxorubicin combined with bevacizumab followed by bevacizumab monotherapy in patients with advanced Kaposi sarcoma. Clinical Cancer Research, 25(14), 4238-4247.
42. Cho, H., Lai, T. C., Tomoda, K., et al. (2015). Polymeric micelles for multi-drug delivery in cancer. Aaps Pharmscitech, 16(1), 10-20.
43. Zhou, M., Hou, J., Zhong, Z., et al. (2018). Targeted delivery of hyaluronic acid-coated solid lipid nanoparticles for rheumatoid arthritis therapy. Drug delivery, 25(1), 716-722.
44. Berget, C., Messer, L. H., & Forlenza, G. P. (2019). A clinical overview of insulin pump therapy for the management of diabetes: past, present, and future of intensive therapy. Diabetes spectrum: a publication of the American Diabetes Association, 32(3), 194.
45. Sabbagh Dit Hawasli, R., Barton, S., & Nabhani-Gebara, S. (2021). Ambulatory chemotherapy: Past, present, and future. Journal of Oncology Pharmacy Practice, 27(4), 962-973.
46. Lee, D. H., & de la Torre Hernandez, J. M. (2018). The newest generation of drug-eluting stents and beyond. European Cardiology Review, 13(1), 54.
47. Cao, Y., Samy, K. E., Bernards, D. A., et al. (2019). Recent advances in intraocular sustained-release drug delivery devices. Drug discovery today, 24(8), 1694-1700.
48. Yang, R., Wei, T., Goldberg, H., et al. (2017). Getting drugs across biological barriers. Advanced Materials, 29(37), 1606596.
49. Ilan, Y. (2020). Overcoming compensatory mechanisms toward chronic drug administration to ensure long-term, sustainable beneficial effects. Molecular Therapy Methods & Clinical Development, 18, 335-344.
50. Spadari, C. D. C., de Bastiani, F. W. M. D. S., Lopes, L. B., et al. (2019). Alginate nanoparticles as non-toxic delivery system for miltefosine in the treatment of candidiasis and cryptococcosis. International Journal of Nanomedicine,14, 5187-5199.
51. Shahriari, M. H., Salmani, H., Akrami, M., et al. (2024). Development of a facile, versatile and scalable fabrication approach of solid, coated, and dissolving microneedle devices for transdermal drug delivery applications. Giant, 18, 100284.
52. Leong, H. S., Butler, K. S., Brinker, C. J., et al. (2019). On the issue of transparency and reproducibility in nanomedicine. Nature nanotechnology, 14(7), 629-635.
53. Geraili, A., Xing, M., & Mequanint, K. (2021). Design and fabrication of drug‐delivery systems toward adjustable release profiles for personalized treatment. View, 2(5), 20200126.
54. Cai, W., Wang, J., Chu, C., et al. (2019). Metal–organic framework‐based stimuli‐responsive systems for drug delivery. Advanced Science, 6(1), 1801526.
55. Mitchell, M. J., Billingsley, M. M., Haley, R. M., et al. (2021). Engineering precision nanoparticles for drug delivery. Nature reviews drug discovery, 20(2), 101-124.
56. Ribeiro, L. N., Alcântara, A. C., Rodrigues da Silva, G. H., et al. (2017). Advances in Hybrid Polymer‐Based Materials for Sustained Drug Release. International Journal of Polymer Science, 2017(1), 1231464.